Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: Behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine

Experimental Brain Research

Volumn 117, Issue 1, 1997, Pages 111-119

  Sautter, Jürgen ^a,b,c   Kupsch, Andreas ^a,b   Earl, Christopher D ^a,b,d   Oertel, Wolfgang H ^a,b,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

6 hydroxydopamine lesion; Dopamine; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; FLUOROGOLD; HOMOVANILLIC ACID; NEUROTROPHIC FACTOR; NIMODIPINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; IMMUNOCYTOCHEMISTRY; MESENCEPHALON; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TIME;

ANIMALS; BEHAVIOR, ANIMAL; CALCIUM CHANNEL BLOCKERS; DOPAMINE; FEMALE; IMMUNOHISTOCHEMISTRY; INJECTIONS; NERVE DEGENERATION; NEURONS; NIMODIPINE; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; SUBSTANTIA NIGRA; SYMPATHOLYTICS;

EID: 0030767710     PISSN: 00144819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002210050204     Document Type: Article

References (66)

1. Altar CA, Marien MR, Marshall JF (1987) Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J Neurochem 48: 390-399
2. Angelov DN, Neiss WF, Streppel M, Andermahr J, Mader K, Stennert E (1996) Nimodipine accelerates axonal sprouting after surgical repair of rat facial nerve. J Neurosci 16: 1041-1048
3. Azmitia EC (1989) Nimodipine attenuates NMDA- and MDMA-induced toxicity of cultured fetal serotonergic neurons: evidence for a generic model of calcium toxicity. In: Traber J, Gispen WH (eds) Nimodipine and central nervous system function: new vistas. Schattauer, Stuttgart, pp 141-159
4. Bär PR, Traber J, Schuurmann T, Gispen WH (1990) CNS and PNS effects of nimodipine. J Neural Transm [Suppl] 31: 55-71
5. Berger K, Przedborski S, Cadet JL (1991) Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull 26: 301-307
6. Bourson A, Gower AJ, Mir AK, Moser PC (1989) The effects of dihydropyridine compounds in behavioral tests of dopamine activity. Br J Pharmacol 98: 1312-1318
7. Breese GR, Traylor TD (1970) Effect of 6-hydroxydopamine on brain norepinephrine and dopamine: evidence for selective degeneration of catecholamine neurons. J Pharmacol Exp Ther 174: 413-420
8. Brundin P, Duan WM, Sauer H (1994) Functional effects of mesencephalic dopamine neurons and adrenal chromaffin cells grafted to the rodent striatum. In: Dunnett SB, Björklund A (eds) Functional neural transplantation. Raven Press, New York, pp 9-46
9. Cadet JL, Last R, Kostic V, Przedborski S, Jackson-Lewis V (1991) Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen. Brain Res Bull 26: 707-713
10. Chiueh CC, Miyake H, Peng M-T (1993) Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism. In: Narabayashi H, Nagutsu T, Yanagisawa N, Mizuno Y (eds) Adv Neurol 60: 251-258
11. Choi DW (1988) Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 11: 465-469
12. Cohen G, Heikkila RE (1973) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249: 2447-2452
13. Dravid A, Jaton AL, Enz A, Björklund A (1984) Spontaneous recovery from motor asymmetry in adult rats with 6-hydroxydopamine-induced partial lesions of the nigrostriatal pathway. Brain Res 311: 361-365
14. Espino A, Cutillas B, Tortosa A, Ferrer I, Bartrons R, Ambrosio S (1995) Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenyl-pyridinium studied by microdialysis in freely moving rats. Brain Res 695: 151-157
15. Fornstedt B (1990) Role of catechol autoxidation in the degeneration of dopamine neurons. Acta Neurol Scand Suppl 129: 12-4
16. 2+-indticed neurotoxicity in rat primary cortical cultures: involvement of L-type calcium channel. Brain Res 654: 257-264
17. Fung YK, Uretsky NJ (1980) The importance of calcium in amphetamine induced turning behavior in mice with unilateral nigrostriatal lesions. Neuropharmacology 19: 555-560
18. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103: 987-1041
19. Gerlach M, Russ H, Winker J, Witzmann K, Traber J, Stasch J-P, Riederer P, Przuntek H (1993) Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice. Arzneimittelforschung Drug Res 43: 413-415
20. Gerlach M, Riederer P, Youdim MBH (1996) Molecular mechanisms for neurodegeneration: synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Adv Neurol 69: 177-194
21. Glinka Y, Youdim MBH (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol Environm Toxicol Pharmacol Sect 295: 329-332
22. Hefti F, Melamed E, Suhakian BJ, Wurtman RJ (1980a) Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and I-DOPA. Pharmacol Biochem Behav 12: 185-188
23. Hefti F, Melamed E, Wurtman RJ (1980b) Partial lesions of the dopaminergic nigrostriatal system in the rat: biochemical characterization. Brain Res 195: 209-217
24. Heikkila RE, Cohen G (1971) Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine. Science 172: 1257-1258
25. Herrera-Marschitz M, Ungerstedt U (1984) Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptors. Eur J Pharmacol 98: 165-76
26. Hirsch E (1992) Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann Neurol 32: 88-93
27. Hökfelt T, Ungerstedt U (1973) Specifity of 6-hydroxydopamine induced degeneration of central monoamine neurones: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigrostriatal dopamine system. Brain Res 60: 269-297
28. Hudson JL, van Horne CG, Strömberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626: 167-174
29. Ichitani Y, Okamura H, Matsumoto Y, Nagatsu I, Ibata Y (1991) Degeneration of the nigral dopamine neurons after 6-hydroxydopamine injection into the rat striatum. Brain Res 549: 350-353
30. Ichitani Y, Okamura H, Nakahara D, Nagatsu I, Ibata Y (1994) Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra. Exp Neurol 130: 269-278
31. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173-2177
32. Javoy F, Sotelo C, Herbet A, Agid Y (1976) Specificity of dopaminergic neuron degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system. Brain Res 102: 201-216
33. Jenner P, Schapira AHV, Marsden CD (1992) New insights into the cause of Parkinson's disease. Neurology 42: 2241-2250
34. Jeon BS, Jackson-Lewis V, Burke RE (1995) 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 4: 131-137
35. Jones BE, Boylan CB, Fritsche M, Juhasz M, Jackson C, Wiegand SJ, Hyman C, Lindsay RM, Altar CA (1996) A continuous striatal infusion of 6-hydroxydopamine produces a terminal axotomy and delayed behavioral effects. Brain Res 709: 275-284
36. Jonsson G (1980) Chemical neurotoxins as denervation tools in neurobiology. Annu Rev Neurosci 3: 169-187
37. Kappelle AC, Biessels G, Van Buren T, Brakkee JH, Gispen WH (1994) Influence of dihydropyridines on the recovery of sensory function after caudal nerve crush in the rat. Restor Neurol Neurosci 6: 271-276
38. Kumar R, Agarwal AK, Seth PK (1995) Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 64: 1703-1707
39. Kupsch A, Löschmann P-A, Sauer H, Arnold G, Renner P, Pufal D, Burg M, Wachtel H, ten Bruggencate G, Oertel WH (1992) Do NMDA receptor antagonists protect against MPTP toxicity? Biochemical and immunocytochemical analyses in a mouse model of Parkinson's disease. Brain Res 592: 74-83
40. Kupsch A, Gerlach M, Pupeter SC, Sautter J, Dirr A, Arnold G, Opitz W, Przuntek H, Riederer P, Oertel WH (1995) Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the strialal level in mice. Neuroreport 6: 621-625
41. Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH (1996) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 741: 185-196
42. 2+ antagonist nimodipine: influence of aging and developmental drug treatment. Neurodegeneration 4: 307-314
43. Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Neuropharmacol 11: 379-387
44. Mena MA, Yébenes MJG de, Tabernero C, Casarejos MJ, Pardo B, Yébenes JG de (1995) Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 18: 410-426
45. Mück W, Bode H (1994) Bioanalytics of nimodipine: an overview of methods. Pharmazie 49: 130-139
46. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM (1996) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 15: 436-447
47. Pifl C, Giros B, Caron MG (1993) Dopamine transporter expression confers cytotoxicity to low doses of parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-pyridinium. J Neurosci 13: 4246-4253
48. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67: 631-647
49. Raaf S (1993) Die intrastriatale 6-OHDA-Läsion der Ratte: Verhaltensphysiologische, histologische und biochemische Charakterisierung eines neuen Parkinson-Modells. Doctoral thesis, University of Munich
50. Robinson TE, Mocsary Z, Camp DM, Wishaw IQ (1994) Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal system. J Neurosci 14: 2687-2696
51. Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59: 401-415
52. Sauer H, Rosenblad C, Björklund A (1995) GDNF but not TGFβ prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 92: 8935-8939
53. Schmidt RH, Björklund A, Stenevi U, Dunnett SB, Gage FH (1983) Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. Acta Physiol Scand Suppl 522: 19-28
54. Sotelo C, Javoy F, Agid Y, Glowinski J (9973) Injection of 6-hydroxydopamine in the substantia nigra of the rat. I. Morphological study. Brain Res 58: 269-290
55. Stuiver BT, Douma BRK, Bakker R, Nyakas C, Luiten PGM (1996) In vivo protection against NMDA-induced neurodegeneration by Mk-801 and nimodipine: combined therapy and temporal course of protection. Neurodegeneration 5: 153-159
56. +) in mice. Eur J Pharmacol 131: 289-292
57. Tomac A, Widenfalk J, Lin L-FH, Kohno T, Ebendahl T, Hoffer BJ, Olson L (1995) Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci USA 92: 8274-8278
58. + neurotoxicity. Nature 349: 414-418
59. Ungerstedt U (1968) 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5: 107-110
60. Ungerstedt U (1971a) Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behavior. Acta Physiol Scand Suppl 367: 49-68
61. Ungerstedt U (1971b) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand Suppl 367: 69-93
62. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493
63. Zetterström T, Herrrera-Marschitz M, Ungerstedt U (1986) Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res 376: 1-7
64. Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM (1984) Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 41: 856-861
65. Zigmond MJ, Berger TW, Grace AA, Stricker EM (1989) Compensatory responses to nigrostriatal bundle injury. Mol Chem Neuropathol 10: 185-199
66. Zigmond MJ, Hastings TG, Abercrombie ED (1992) Neurochemical responses to 6-hydroxydopamine and 1-dopa therapy: implications for Parkinson's disease. Ann NY Acad Sci 648: 71-86